Literature DB >> 19553658

Molecular outcome prediction in diffuse large-B-cell lymphoma.

Ash A Alizadeh, Andrew J Gentles, Izidore S Lossos, Ronald Levy.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19553658     DOI： 10.1056/NEJMc0902616

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

1.  Buckley-James boosting for survival analysis with high-dimensional biomarker data.

Authors:  Zhu Wang; C Y Wang
Journal:  Stat Appl Genet Mol Biol       Date:  2010-06-08

2.  Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma.

Authors:  Javeed Iqbal; Yulei Shen; Xin Huang; Yanyan Liu; Laura Wake; Cuiling Liu; Karen Deffenbacher; Cynthia M Lachel; Chao Wang; Joseph Rohr; Shuangping Guo; Lynette M Smith; George Wright; Sharathkumar Bhagavathi; Karen Dybkaer; Kai Fu; Timothy C Greiner; Julie M Vose; Elaine Jaffe; Lisa Rimsza; Andreas Rosenwald; German Ott; Jan Delabie; Elias Campo; Rita M Braziel; James R Cook; Raymond R Tubbs; James O Armitage; Dennis D Weisenburger; Louis M Staudt; Randy D Gascoyne; Timothy W McKeithan; Wing C Chan
Journal:  Blood       Date:  2014-12-10       Impact factor: 22.113

3.  Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment.

Authors:  Ash A Alizadeh; Andrew J Gentles; Alvaro J Alencar; Chih Long Liu; Holbrook E Kohrt; Roch Houot; Matthew J Goldstein; Shuchun Zhao; Yasodha Natkunam; Ranjana H Advani; Randy D Gascoyne; Javier Briones; Robert J Tibshirani; June H Myklebust; Sylvia K Plevritis; Izidore S Lossos; Ronald Levy
Journal:  Blood       Date:  2011-06-13       Impact factor: 22.113

4.  LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.

Authors:  Salma Parvin; Ariel Ramirez-Labrada; Shlomzion Aumann; XiaoQing Lu; Natalia Weich; Gabriel Santiago; Elena M Cortizas; Eden Sharabi; Yu Zhang; Isidro Sanchez-Garcia; Andrew J Gentles; Evan Roberts; Daniel Bilbao-Cortes; Francisco Vega; Jennifer R Chapman; Ramiro E Verdun; Izidore S Lossos
Journal:  Cancer Cell       Date:  2019-08-22       Impact factor: 31.743

Review 5.  Molecular pathogenesis of diffuse large B-cell lymphoma.

Authors:  Christof Schneider; Laura Pasqualucci; Riccardo Dalla-Favera
Journal:  Semin Diagn Pathol       Date:  2011-05       Impact factor: 3.464

6.  Inferring gene expression from cell-free DNA fragmentation profiles.

Authors:  Mohammad Shahrokh Esfahani; Emily G Hamilton; Mahya Mehrmohamadi; Barzin Y Nabet; Stefan K Alig; Daniel A King; Chloé B Steen; Charles W Macaulay; Andre Schultz; Monica C Nesselbush; Joanne Soo; Joseph G Schroers-Martin; Binbin Chen; Michael S Binkley; Henning Stehr; Jacob J Chabon; Brian J Sworder; Angela B-Y Hui; Matthew J Frank; Everett J Moding; Chih Long Liu; Aaron M Newman; James M Isbell; Charles M Rudin; Bob T Li; David M Kurtz; Maximilian Diehn; Ash A Alizadeh
Journal:  Nat Biotechnol       Date:  2022-03-31       Impact factor: 68.164

Review 7.  Molecular pathology of lymphoma.

Authors:  S E Coupland
Journal:  Eye (Lond)       Date:  2012-12-07       Impact factor: 3.775

Review 8.  The Global Landscape of EBV-Associated Tumors.

Authors:  Claire Shannon-Lowe; Alan Rickinson
Journal:  Front Oncol       Date:  2019-08-06       Impact factor: 6.244

9.  An integrated prognosis model of pharmacogenomic gene signature and clinical information for diffuse large B-cell lymphoma patients following CHOP-like chemotherapy.

Authors:  Jinglei Hu; Jing Xu; Muqiao Yu; Yongchao Gao; Rong Liu; Honghao Zhou; Wei Zhang
Journal:  J Transl Med       Date:  2020-03-30       Impact factor: 5.531

10.  The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research.

Authors:  Alexandra Smith; Eve Roman; Debra Howell; Richard Jones; Russell Patmore; Andrew Jack
Journal:  Br J Haematol       Date:  2009-12-01       Impact factor: 6.998
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.